Prof. MD.İrfan Çiçin

With over 100 publications in leading oncology journals, Prof. Dr. İrfan Çiçin is advancing global standards in molecular and systemic cancer therapy.

Professor Dr. İrfan Çiçin is a leading figure in Medical Oncology, renowned for providing world-class care and achieving outstanding clinical outcomes in the comprehensive management of cancer. Practicing at İstinye University Liv Hospital Topkapı, Dr. Çiçin’s expertise spans a vast range of malignancies, including Breast Cancer, Lung Cancer, Colorectal Cancers, and complex Gynecological and Urogenital Cancers. His core commitment is to a deeply patient-centric philosophy, ensuring that treatment is tailored to the individual's unique molecular profile and personal well-being, prioritizing both efficacy and patient comfort. Dr. Çiçin utilizes the latest cutting-edge technology to deliver advanced treatments, including modern forms of Immunotherapy (like Nivolumab and Cemiplimab for metastatic renal cell carcinoma and NSCLC, respectively), targeted therapies (such as CDK 4/6 inhibitors for breast cancer, and ALK TKIs for lung cancer), and novel chemotherapy agents (like trifluridine/tipiracil for colorectal and gastric cancer).

His involvement in major international clinical trials, such as the monarchE study for high-risk early breast cancer and the EMPOWER-Lung 1 study for non-small cell lung cancer, ensures his patients have access to the most revolutionary therapies and strategies before they are widely available. This integration of global clinical research directly into his practice is a testament to his high level of clinical expertise. By specializing in Molecular Oncology, he uses sophisticated diagnostics to pinpoint the genetic drivers of cancer, enabling minimally invasive and highly precise drug therapies that lead to faster recovery and significantly improved quality of life for patients battling advanced or metastatic disease.

Professor Dr. İrfan Çiçin holds a preeminent position as an academic authority in oncology, consistently integrating his vast experience with rigorous scientific research to elevate clinical standards. Achieving his professorship at Trakya University Faculty of Medicine, Dr. Çiçin’s career reflects a powerful commitment to evidence-based medicine and an inherent educator role. His extensive academic output includes a wealth of publications,spanning over two decades,in major international oncology journals like The Lancet Oncology, JAMA Oncology, and Critical Reviews in Oncology/Hematology. This body of work is a critical resource for the global oncology community.

His scientific research focuses on challenging therapeutic sequences in metastatic disease, investigating prognostic factors, analyzing real-world treatment outcomes, and exploring supportive care strategies (such as the effect of Saccharomyces boulardii on abemaciclib-induced diarrhea). Dr. Çiçin's leadership extends beyond publication, as he is actively involved in large, multi-center, international clinical trials and consortiums, including the Turkish Oncology Group Kidney Cancer Consortium (TKCC) and major European and American study groups. This participation not only validates his expertise but confirms that his treatment recommendations are derived from the highest level of scientific evidence. By continuously contributing to translational and clinical research, Dr. Çiçin maintains a standard of care informed by prestigious certification levels of diagnostics and the most current scientific knowledge, cementing his status as a key scientific leader in both the diagnosis and systemic treatment of malignancies.